Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab, Axitinib, and Avelumab in Advanced HCC
NCT05249569Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bavituximab in hepatocellular carcinoma (HCC), sponsored by UT Southwestern Medical Center. Started Nov 2022; status: terminated.
02
Drugs
bavituximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05249569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249569.